Biphasic Feature of Placebo Response in Primary Insomnia: Pooled Analysis of Data from Randomized Controlled Clinical Trials of Orexin Receptor Antagonists.
The placebo response to orexin receptor antagonists in primary insomnia is little-known. Our aim was therefore to conduct a systematic review of placebo-controlled randomized clinical trials to characterize placebo response. We performed a comprehensive literature search for randomized, placebo-controlled, double-blind clinical trials evaluating the efficacy of orexin receptor antagonists addressing primary insomnia. To pool effect size estimates (Cohen's d) of placebo and orexin receptor antagonists across trials for outcome measures, a meta-analysis was done according to the Cochrane guideline. The placebo response was significant and robust to improve the symptoms of insomnia in terms of objective and subjective measures, and the effects (0.70 ± 0.51) in subjective measures were smaller than that (1.10 ± 1.14) in objective measures (p = 0.027). The biphasic feature of placebo response showed an initial short-term increase of placebo effect, and subsequent changeless long-term effect. The biphasic feature of placebo response is clinically useful, and neuroimaging is essential to clarify the long-term mechanism in the future.